Alemtuzumab in the treatment of active relapsing-remitting multiple sclerosis: Croatian multicenter, observational study

被引：0
|
作者：
Habek, M. [1 ]
Kes, V. Basic [2 ]
Lazibat, I. [3 ]
Piskac, S. Kidemet [4 ]
Ratkovic, M. [5 ]
Komso, M. [6 ]
Raspopovic, A. Bogoje
Barun, B. [1 ]
Skoric, M. Krbot
机构：
[1] Univ Zagreb, Sch Med, Zagreb, Croatia
[2] Univ Hosp Ctr Sestre milosrdnice, Zagreb, Croatia
[3] Univ Hosp Dubrava, Zagreb, Croatia
[4] Gen Hosp Varazdin, Varazhdin, Croatia
[5] Gen Hosp Slavonski Brod, Slavonski Brod, Croatia
[6] Gen Hosp Zadar, Zadar, Croatia
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2020年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO1239
引用
收藏
页码：671 / 671
页数：1
相关论文
共 50 条
  • [1] Effectiveness and safety of alemtuzumab in the treatment of active relapsing-remitting multiple sclerosis: a multicenter, observational study
    Brecl Jakob, Gregor
    Barun, Barbara
    Gomezelj, Sarah
    Gabelic, Tereza
    Sega Jazbec, Sasa
    Adamec, Ivan
    Horvat Ledinek, Alenka
    Rot, Uros
    Krbot Skoric, Magdalena
    Habek, Mario
    [J]. NEUROLOGICAL SCIENCES, 2021, 42 (11) : 4591 - 4597
  • [2] Effectiveness and safety of alemtuzumab in the treatment of active relapsing–remitting multiple sclerosis: a multicenter, observational study
    Gregor Brecl Jakob
    Barbara Barun
    Sarah Gomezelj
    Tereza Gabelić
    Saša Šega Jazbec
    Ivan Adamec
    Alenka Horvat Ledinek
    Uroš Rot
    Magdalena Krbot Skorić
    Mario Habek
    [J]. Neurological Sciences, 2021, 42 : 4591 - 4597
  • [3] Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis
    Hersh, Carrie M.
    Cohen, Jeffrey A.
    [J]. IMMUNOTHERAPY, 2014, 6 (03) : 249 - 259
  • [4] Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis
    Fox, Edward J.
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2010, 10 (12) : 1789 - 1797
  • [5] Effectiveness of cladribine tablets in the treatment of active relapsing-remitting multiple sclerosis: a multicenter, observational study
    Habek, M.
    Brecl, G. Jakob
    Rajda, C.
    Adamec, I.
    Barun, B.
    Rok, A.
    Ledinek, A. Horvat
    Rot, U.
    Jazbec, S. Sega
    Gabelic, T.
    Klivenyi, P.
    Skoric, M. Krbot
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 894 - 894
  • [6] Alemtuzumab: A new therapy for active relapsing-remitting multiple sclerosis
    Hartung, Hans-Peter
    Aktas, Orhan
    Boyko, Alexey N.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (01) : 22 - 34
  • [7] Safety of alemtuzumab by treatment course in patients with active relapsing-remitting multiple sclerosis
    Clanet, M.
    Hunter, S. F.
    Palmer, J.
    Oyuela, P.
    Margolin, D. H.
    [J]. JOURNAL OF NEUROLOGY, 2014, 261 : S300 - S300
  • [8] Safety of alemtuzumab by treatment course in patients with active relapsing-remitting multiple sclerosis
    Clanet, M.
    Hunter, S. F.
    Palmer, J.
    Oyuela, P.
    Margolin, D. H.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 453 - 453
  • [9] Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis
    Iovino, Aniello
    Aruta, Francesco
    Carotenuto, Antonio
    Manganelli, Fiore
    Iodice, Rosa
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 28 : 98 - 100
  • [10] Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study
    Totaro, Rocco
    Di Carmine, Caterina
    Costantino, Gianfranco
    Fantozzi, Roberta
    Bellantonio, Paolo
    Fuiani, Aurora
    Mundi, Ciro
    Ruggieri, Stefano
    Marini, Carmine
    Carolei, Antonio
    [J]. MULTIPLE SCLEROSIS INTERNATIONAL, 2015, 2015
12345